Drug
Elexacaftor clinical trials
- studies test it
- 23
- open now
- 2
- in phase 3
- 19
- first study started
- 2017
Keep track of what changes. Save the elexacaftor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
23 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 19
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 3
Vertex Pharmaceuticals Incorporated (20) · Royal College of Surgeons, Ireland (1) · Istituto Giannina Gaslini (1) · Arkansas Children's Hospital Research Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses elexacaftor is read from its arms, and is right about nine times in ten.
Testing it · 23
- Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic FibrosisRecruitingPhase 4Istituto Giannina GasliniNCT07809867Written as Elexacaftor, Tezacaftor, Ivacaftor
- Ensuring Access to Optimal Therapy in CF: The ENACT StudyRecruitingPhase 4Arkansas Children's Hospital Research InstituteNCT07148739Written as Elexacaftor / Ivacaftor / Tezacaftor
- Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05882357Written as ELX/TEZ/IVA
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delActive, not recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT05331183Written as ELX/TEZ/IVA
- Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)Active, not recruitingPhase 4Royal College of Surgeons, IrelandNCT04602468Written as Elexacaftor/Tezacaftor/Ivacaftor
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderActive, not recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT06460506Written as ELX/TEZ/IVA
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05153317Written as ELX/TEZ/IVA
- A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03525574Written as ELX/TEZ/IVA
- A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04969224Written as ELX/TEZ/IVA
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and OlderCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04183790Written as ELX/TEZ/IVA
- Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05274269Written as ELX/TEZ/IVA
- A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF GenotypesCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04545515Written as ELX/TEZ/IVA
- Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04058366Written as ELX/TEZ/IVA
- A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04599465Written as ELX/TEZ/IVA
- A Study Evaluating the Long-Term Safety of Elexacaftor Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04362761Written as ELX/TEZ/IVA
- A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05111145Written as ELX/TEZ/IVA
- A Study Evaluating the Long-term Safety of VX-445 Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04043806Written as ELX/TEZ/IVA
- Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04537793Written as ELX/TEZ/IVA
- A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF GenotypesCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04353817Written as ELX/TEZ/IVA
- A Study of VX-445 in Healthy Subjects and Subjects With Cystic FibrosisCompletedPhase 1/2Vertex Pharmaceuticals IncorporatedNCT03227471Written as VX-445
See all 23 studies that test elexacaftor →
Given in every arm · 1 — elexacaftor is usual care beside what is tested
As the comparator · 2 — what is tested is compared with elexacaftor
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05033080Written as ELX/TEZ/IVA
- A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05076149Written as ELX/TEZ/IVA
Codes
What other systems call elexacaftor · ClinicalTrials.gg INT001009
- MeSH (NLM) C000629074elexacaftorConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RRN67GMB0VELEXACAFTORConfirmed FDA, NLM, Wikidata
- RxNorm 2256951Confirmed FDA, Wikidata
- Wikidata Q72184089elexacaftorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169935ElexacaftorOne source FDA
- DrugBank DB15444One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629074 | elexacaftor | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RRN67GMB0V | ELEXACAFTOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2256951 | — | Confirmed FDA, Wikidata |
| Wikidata | Q72184089 | elexacaftor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169935 | Elexacaftor | One source FDA |
| DrugBank | DB15444 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.